Rethinking Antisense Architecture with Transient Cyclic Oligonucleotides for Next-Generation RNA Therapeutics
Author: Christian Cobaugh, CEO, Genetic Medicine Division at Alloy Therapeutics RNA therapeutics are moving from promise to reality. By operating upstream of protein targets and closer to the genetic root causes of many diseases, RNA medicines often offer treatment approaches that differ fundamentally from conventional small molecules or biologics. Antisense molecules have evolved from conceptual […]
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
Antibody discovery for complex fibrosis targets requires advanced platforms capable of addressing difficult biology. Alloy Therapeutics partnered with Mediar to accelerate high-quality antibody programs into IND-enabling studies.
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines
BOSTON — January 6, 2026 — Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines. Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level. Alloy’s AntiClastic technology is a proprietary cyclic nucleic acid […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
De-risking antibody discovery through comprehensive developability profiling
De-risking antibody discovery through comprehensive developability profiling Download Tech Note Contact Us Select leads with confidence by integrating biophysical assays, computational analysis, and clinical benchmarking from the earliest stages of discovery. Despite strong target binding, many therapeutic antibodies fail late in development due to preventable issues related to stability, manufacturability, or pharmacokinetics. Alloy’s integrated developability […]
Alloy Therapeutics Announces Acquisition of Spannerwerks, a Leading Provider of Drug Development Consulting Services
BOSTON — October 23, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceuticals on the development and launch of new products. Under the terms of the agreement, Spannerwerks will operate […]
Alloy Therapeutics Signs Memorandum of Understanding (MOU) with the Republic of Serbia to Support Global Bioeconomy Initiative
The collaboration extends Alloy’s sovereign innovation efforts to help advance Serbia’s national biotech ambitions through the BIO4 Campus.